ArticlesAdherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
Introduction
In Europe an estimated 10 million patients are affected by heart failure, and in the USA chronic heart failure (CHF) accounts for more than 1 million hospital admissions and more than a quarter of a million deaths every year.1, 2, 3, 4 Although the findings of numerous studies have shown that medications and lifestyle modifications reduce mortality in CHF, adherence to these interventions is often below optimum. Poor adherence limits the effectiveness of proven therapies, resulting in lost opportunities to reduce mortality and readmission rates. Indeed, poor adherence accounts for up to two-thirds of preventable admissions in heart failure and coronary artery disease,5, 6, 7 and is associated with mortality in patients with other chronic illnesses, including breast cancer, asthma, rheumatoid arthritis, and coronary artery disease.8, 9, 10, 11, 12
Improved adherence, even to placebo, is associated with improved survival; in both the Coronary Drug Project (CDP)13 and the Beta Blocker in Heart Attack Trial (BHAT),11 patients on placebo who were highly adherent had lower mortality and fewer cardiovascular events than those who were not. However, in CHF, the nature of the association between adherence and clinical outcomes remains unclear, and efforts to identify patients at risk for poor adherence have been inconclusive.
For this study, therefore, we used patients enrolled to the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme to address two questions: first, does the association between better adherence and lower mortality hold in patients with heart failure; and, second, can factors associated with better adherence be identified in this contemporary cohort of patients followed-up for a long period?
Section snippets
Participants
The CHARM programme and its results have been previously described.14 In summary, patients with symptomatic CHF from 618 sites in 26 countries were enrolled into three concomitant, independent studies with uniform definitions, endpoints, and procedures for randomisation and follow-up. Patients aged 18 years or older who had symptomatic CHF (New York Heart Association [NYHA] class II–IV) for 4 weeks or more before randomisation were eligible for inclusion: CHARM-Alternative15 included patients
Results
7599 patients were enrolled to the CHARM programme: 2028 to CHARM-Alternative,15 2548 to CHARM-Added,16 and 3023 (of which two patients left out of analysis) to CHARM-Preserved.17 Of these, we excluded 187 patients from the adherence analysis because of missing information on adherence. The mean baseline age of patients enrolled was 66 years, and females comprised 32% (n=2400) of the sample. Patients had moderate-to-severe CHF; at baseline they were predominantly in NYHA functional class II or
Discussion
The CHARM dataset provided an opportunity to examine the association between adherence and mortality in a large, contemporary cohort of patients with symptomatic CHF and a wide range of ejection fractions. Moreover, the placebo group provided an opportunity to assess how much of the advantage associated with better adherence is unrelated to the effect of active treatment. Our findings extend the findings of two randomised clinical trials of patients with myocardial infarction—namely, CDP13 and
References (53)
- et al.
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET
Am Heart J
(2005) - et al.
Self-care abilities of patients with heart failure
Heart Lung
(2001) - et al.
Treatment adherence and risk of death after a myocardial infarction
Lancet
(1990) - et al.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
Lancet
(2003) - et al.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Lancet
(2003) Predictors of medication adherence in the elderly
Clin Ther
(1998)- et al.
Relationship between psychosocial variables and compliance in patients with heart failure
Heart Lung
(2001) - et al.
Preventable smoking and exercise-related hospital admissions: a model based on the NHEFS
Am J Prev Med
(2001)
Decompensated heart failure: symptoms, patterns of onset, and contributing factors
Am J Med
Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study
J Card Fail
A story of maladies, misconceptions and mishaps: effective management of heart failure
Soc Sci Med
Placebos, active control groups, and the unpredictability paradox
Biol Psychiatry
Developing improved observational methods for evaluating therapeutic effectiveness
Am J Med
The current cost of heart failure to the National Health Service in the UK
Eur J Heart Fail
Heart disease and stroke statistics: 2005 update
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Eur Heart J
Characterization of the precipitants of hospitalization for heart failure decompensation
Am J Crit Care
Precipitating factors leading to decompensation of heart failure: traits among urban blacks
Arch Intern Med
Medication adherence in rheumatoid arthritis patients: older is wiser
J Am Geriatr Soc
Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge
Eur J Heart Fail
Adherence with twice-daily dosing of inhaled steroids: socioeconomic and health-belief differences
Am J Respir Crit Care Med
Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study
Psychosom Med
Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project
N Engl J Med
Psychosocial influences on mortality after myocardial infarction
N Engl J Med
Cited by (414)
Adherence to antihypertensive medications
2024, Archives des Maladies du Coeur et des Vaisseaux - PratiqueTreatment Adherence in a Randomized Controlled Trial of Pirfenidone in HFpEF: Determinants and Impact on Efficacy
2023, Journal of Cardiac FailureMedication adherence in tobacco cessation clinical trials
2023, Addiction NeuroscienceCoronary heart disease in obstructive sleep apnea
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second EditionOutcomes of Myocardial Revascularization in Diabetic Patients With Left Main Coronary Artery Disease: A Multicenter Observational Study From Three Gulf Countries
2023, Cardiovascular Revascularization MedicineUnprotected Left Main Revascularization in the Setting of Non-coronary Atherosclerosis: Gulf Left Main Registry
2023, Current Problems in Cardiology